Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Hidradenitis Suppurativa Treatment Market: By Clinical Stage Drug Type By Distribution Channel and Region Forecast 2019-2030
Hidradenitis Suppurativa Treatment Market size was valued at US$ 721.9 million in 2023 and is expected to grow at a prominent growth rate of 4.5% from 2024 to 2030. The global market provides a detailed overview of the global market, and that can be segmented by Clinical Stage, Drug Type, and by Distribution Channel. By Clinical Stage, the global market has been segmented into Hurley Stage 1, Hurley Stage 2, and Hurley Stage 3. The Hurley stage 1 Suppurativa Treatment segment is likely to be the largest and fastest-growing segment in terms of type. Based on Drug type, the global market is segmented into Biologics, Antibiotics, Hormonal therapy, Immune suppurativa drugs, Pain medications, and Others. Among these, the biologics segment is expected to have the fastest-growing market during the forecast period.
Study Period
2024-2030Base Year
2023CAGR
4.5%Largest Market
North AmericanFastest Growing Market
Asia-Pacific
Number of cases of various skin conditions has increased, and the FDA is approving more drugs and clinical trials are burgeon the market growth over the forecast years.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 721.9 million |
Market CAGR |
4.5% |
By Clinical Stage |
|
By Drug Type |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global hidradenitis suppurativa treatment market size was valued at US$ 721.9 million in 2023 and is grow at CAGR of 4.8 from 2024 to 2030
High treatment costs, drug resistance, and unmet medical needs are some of the main obstacles thought to significantly impede the expansion of the hidradenitis suppurativa industry.
AstraZeneca (UK), Pfizer Inc.(US), GlaxoSmithKline plc. (UK), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US)
1. Executive Summary |
2. Global Hidradenitis Suppurativa Treatment Market Introduction |
2.1. Global Hidradenitis Suppurativa Treatment Market Taxonomy |
2.2. Global Hidradenitis Suppurativa Treatment Market Definitions |
2.2.1. Clinical Stage |
2.2.2. Drug Type |
2.2.3. Distribution Channel |
3. Global Hidradenitis Suppurativa Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Hidradenitis Suppurativa Treatment Market Dynamic Factors - Impact Analysis |
3.6. Global Hidradenitis Suppurativa Treatment Market Competition Landscape |
4. Global Hidradenitis Suppurativa Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
4.1. Market Analysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Hidradenitis Suppurativa Treatment Market, By Clinical Stage, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1. Hurley Stage 1 |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Hurley Stage 2 |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Hurley Stage 3 |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Hidradenitis Suppurativa Treatment Market Forecast, By Drug Type, 2019 - 2023 and Forecast, 2022 2028 (Revenue, USD Mn) |
6.1. Biologics |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Antibiotics |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Hormonal therapy |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Immune suppurativa drugs |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Pain medications |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Others |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7. Global Hidradenitis Suppurativa Treatment Market, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Hidradenitis Suppurativa Treatment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Hidradenitis Suppurativa Treatment Market - Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel and Region, 2024 - 2030 |
9. North America Hidradenitis Suppurativa Treatment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
9.1. By Clinical Stage Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Hurley Stage 1 |
9.1.2. Hurley Stage 2 |
9.1.3. Hurley Stage 3 |
9.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. Biologics |
9.2.2. Antibiotics |
9.2.3. Hormonal therapy |
9.2.4. Immune suppurativa drugs |
9.2.5. Pain medications |
9.2.6. Others |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Hospital Pharmacies |
9.3.2. Retail Pharmacies |
9.3.3. Online Pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Hidradenitis Suppurativa Treatment Market - Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2024 - 2030 |
9.6. North America Hidradenitis Suppurativa Treatment Market Dynamics Trends |
10. Europe Hidradenitis Suppurativa Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
10.1. By Clinical Stage Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Hurley Stage 1 |
10.1.2. Hurley Stage 2 |
10.1.3. Hurley Stage 3 |
10.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Biologics |
10.2.2. Antibiotics |
10.2.3. Hormonal therapy |
10.2.4. Immune suppurativa drugs |
10.2.5. Pain medications |
10.2.6. Others |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Hospital Pharmacies |
10.3.2. Retail Pharmacies |
10.3.3. Online Pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Poland |
10.4.8. Rest of Europe |
10.5. Europe Hidradenitis Suppurativa Treatment Market - Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2024 - 2030 |
10.6. Europe Hidradenitis Suppurativa Treatment Market Dynamics Trends |
11. Asia-Pacific Hidradenitis Suppurativa Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
11.1. By Clinical Stage Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Hurley Stage 1 |
11.1.2. Hurley Stage 2 |
11.1.3. Hurley Stage 3 |
11.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Biologics |
11.2.2. Antibiotics |
11.2.3. Hormonal therapy |
11.2.4. Immune suppurativa drugs |
11.2.5. Pain medications |
11.2.6. Others |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Hospital Pharmacies |
11.3.2. Retail Pharmacies |
11.3.3. Online Pharmacies |
11.4. Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Japan |
11.4.2. China |
11.4.3. India |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Hidradenitis Suppurativa Treatment Market - Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2024 - 2030 |
11.6. Asia-Pacific Hidradenitis Suppurativa Treatment Market Dynamics Trends |
12. Latin America Hidradenitis Suppurativa Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
12.1. By Clinical Stage Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Hurley Stage 1 |
12.1.2. Hurley Stage 2 |
12.1.3. Hurley Stage 3 |
12.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Biologics |
12.2.2. Antibiotics |
12.2.3. Hormonal therapy |
12.2.4. Immune suppurativa drugs |
12.2.5. Pain medications |
12.2.6. Others |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Hospital Pharmacies |
12.3.2. Retail Pharmacies |
12.3.3. Online Pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Hidradenitis Suppurativa Treatment Market - Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2024 - 2030 |
12.6. Latin America Hidradenitis Suppurativa Treatment Market Dynamics Trends |
13. Middle East and Africa Hidradenitis Suppurativa Treatment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
13.1. By Clinical Stage Analysis 2019 - 2023 and Forecast 2024 - 2030by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Hurley Stage 1 |
13.1.2. Hurley Stage 2 |
13.1.3. Hurley Stage 3 |
13.2. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Biologics |
13.2.2. Antibiotics |
13.2.3. Hormonal therapy |
13.2.4. Immune suppurativa drugs |
13.2.5. Pain medications |
13.2.6. Others |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Hospital Pharmacies |
13.3.2. Retail Pharmacies |
13.3.3. Online Pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Hidradenitis Suppurativa Treatment Market - Opportunity Analysis Index, By Clinical Stage, Drug Type, Distribution Channel, and Country, 2024 - 2030 |
13.6. MEA Hidradenitis Suppurativa Treatment Market Dynamics Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Drug Type& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. AbbVie Inc. |
14.2.2. AstraZeneca plc |
14.2.3. Johnson & Johnson |
14.2.4. Merck & Co., Inc. |
14.2.5. Allergan plc |
14.2.6. Pfizer Inc. |
14.2.7. GlaxoSmithKline plc |
14.2.8. LEO Pharma A/S |
14.2.9. Novartis AG |
14.2.10. AstraZeneca |
15. Research Methodology |
16. Key Assumptions and Acronyms |
Key Market Players